Polypyrimidine-Tract-Binding Protein Isoforms Differentially Regulate the Hepatitis C Virus Internal Ribosome Entry Site

dc.contributor.affiliationPontificia Universidad Catolica de Chile
dc.contributor.affiliationUniversidad Finis Terrae
dc.contributor.affiliationUniversity System of Georgia
dc.contributor.affiliationUniversity of Georgia
dc.contributor.affiliationUniversidad de Las Americas - Chile
dc.contributor.affiliationUniversite Paris Cite
dc.contributor.affiliationCentre National de la Recherche Scientifique (CNRS)
dc.contributor.authorAngulo, Jenniffer
dc.contributor.authorCaceres, C. Joaquin
dc.contributor.authorContreras, Nataly
dc.contributor.authorFernández-García, Leandro
dc.contributor.authorChamond, Nathalie
dc.contributor.authorAmeur, Melissa
dc.contributor.authorSargueil, Bruno
dc.contributor.authorLopez-Lastra, Marcelo
dc.date.accessioned2024-09-03T19:19:10Z
dc.date.available2024-09-03T19:19:10Z
dc.date.issued2022-12-20
dc.description.abstractTranslation initiation of the hepatitis C virus (HCV) mRNA depends on an internal ribosome entry site (IRES) that encompasses most of the 5′UTR and includes nucleotides of the core coding region. This study shows that the polypyrimidine-tract-binding protein (PTB), an RNA-binding protein with four RNA recognition motifs (RRMs), binds to the HCV 5′UTR, stimulating its IRES activity. There are three isoforms of PTB: PTB1, PTB2, and PTB4. Our results show that PTB1 and PTB4, but not PTB2, stimulate HCV IRES activity in HuH-7 and HEK293T cells. In HuH-7 cells, PTB1 promotes HCV IRES-mediated initiation more strongly than PTB4. Mutations in PTB1, PTB4, RRM1/RRM2, or RRM3/RRM4, which disrupt the RRM’s ability to bind RNA, abrogated the protein’s capacity to stimulate HCV IRES activity in HuH-7 cells. In HEK293T cells, PTB1 and PTB4 stimulate HCV IRES activity to similar levels. In HEK293T cells, mutations in RRM1/RRM2 did not impact PTB1′s ability to promote HCV IRES activity; and mutations in PTB1 RRM3/RRM4 domains reduced, but did not abolish, the protein’s capacity to stimulate HCV IRES activity. In HEK293T cells, mutations in PTB4 RRM1/RRM2 abrogated the protein’s ability to promote HCV IRES activity, and mutations in RRM3/RRM4 have no impact on PTB4 ability to enhance HCV IRES activity. Therefore, PTB1 and PTB4 differentially stimulate the IRES activity in a cell type-specific manner. We conclude that PTB1 and PTB4, but not PTB2, act as IRES transacting factors of the HCV IRES.
dc.description.sponsorshipAgencia Nacional de Investigacion y Desarrollo (ANID), Gobierno de Chile through grants FONDECYT [1210736]; Iniciativa Cientifica Milenio (ICM); Instituto Milenio de Inmunologia e Inmunoterapia [P09/016-F, ICN09_016]; ANRS [AO2019-2-19382]; Laboratoire International Associe; This research was funded by the Agencia Nacional de Investigacion y Desarrollo (ANID), Gobierno de Chile through grants FONDECYT 1210736, and the Iniciativa Cientifica Milenio (ICM), Instituto Milenio de Inmunologia e Inmunoterapia (P09/016-F; ICN09_016) to M.L-L. Research in the B.S. laboratory is funded by ANRS (AO2019-2-19382) and a Laboratoire International Associe (LIA-ANDES2) granted by the CNRS for exchanges with the MLL laboratory.
dc.format.mimetypeapplication/pdf
dc.identifier.citationViruses, 15(1), 8. https://doi.org/10.3390/v15010008
dc.identifier.doihttps://doi.org/10.3390/v15010008
dc.identifier.folio1210736
dc.identifier.issn1999-4915
dc.identifier.orcidhttps://orcid.org/0000-0002-0471-4751
dc.identifier.orcidhttps://orcid.org/0000-0001-8508-6592
dc.identifier.orcidhttps://orcid.org/0000-0001-5981-5632
dc.identifier.orcidhttps://orcid.org/0000-0002-0518-2929
dc.identifier.orcidhttps://orcid.org/0000-0003-4483-355X
dc.identifier.orcidhttps://orcid.org/0000-0002-7936-8478
dc.identifier.pmid36680049
dc.identifier.researcheridAFL-9098-2022
dc.identifier.researcheridHJA-6849-2022
dc.identifier.researcheridAAS-1536-2021
dc.identifier.researcheridHHM-9832-2022
dc.identifier.researcheridKMY-5962-2024
dc.identifier.researcheridC-5907-2018
dc.identifier.researcheridHKE-2558-2023
dc.identifier.rorhttps://ror.org/04teye511
dc.identifier.rorhttps://ror.org/0225snd59
dc.identifier.rorhttps://ror.org/00te3t702
dc.identifier.rorhttps://ror.org/0166e9x11
dc.identifier.rorhttps://ror.org/02feahw73
dc.identifier.rorhttps://ror.org/05f82e368
dc.identifier.rorhttps://ror.org/001z21q04
dc.identifier.rorhttps://ror.org/05cbrk226
dc.identifier.scopusauthorid56684392200
dc.identifier.scopusauthorid57220091773
dc.identifier.scopusauthorid57188742461
dc.identifier.scopusauthorid57219445210
dc.identifier.scopusauthorid6602384117
dc.identifier.scopusauthorid57188733548
dc.identifier.scopusauthorid6602105297
dc.identifier.scopusauthorid6602810426
dc.identifier.urihttps://repositorio.udla.cl/handle/udla/1424
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.fundingIniciativa Cientifica Milenio
dc.relation.fundingLaboratoire International Associé
dc.relation.fundingFondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT, (1210736)
dc.relation.fundingFondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT
dc.relation.fundingAgence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS, (AO2019-2-19382)
dc.relation.fundingAgence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS
dc.relation.fundingCentre National de la Recherche Scientifique, CNRS
dc.relation.fundingInstituto Milenio en Inmunología e Inmunoterapia, MIII, (ICN09_016)
dc.relation.fundingInstituto Milenio en Inmunología e Inmunoterapia, MIII
dc.relation.fundingAgencia Nacional de Investigación y Desarrollo, ANID
dc.relation.fundingAgencia Nacional de Investigacion y Desarrollo (ANID), Gobierno de Chile through grants FONDECYT [1210736]
dc.relation.fundingIniciativa Cientifica Milenio (ICM)
dc.relation.fundingInstituto Milenio de Inmunologia e Inmunoterapia [P09/016-F, ICN09_016]
dc.relation.fundingANRS [AO2019-2-19382]
dc.relation.isindexedbyWeb of Science
dc.relation.issn1999-4915
dc.rightsCreative Commons Attribution 4.0 International
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceViruses
dc.source.urihttps://doi.org/10.3390/v15010008
dc.subjectHCV
dc.subjectIRES
dc.subjectPTB
dc.subjectITAF
dc.subject.lcshHepacivirus
dc.subject.lcshHepatitis C
dc.subject.oecd11 Ciencias Naturales
dc.subject.oecd21.6 Ciencias Biológicas
dc.subject.oecd31.6.3 Virología
dc.titlePolypyrimidine-Tract-Binding Protein Isoforms Differentially Regulate the Hepatitis C Virus Internal Ribosome Entry Site
dc.typejournal article
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.udla.catalogadorCBM
oaire.citation.issue1
oaire.citation.titleViruses
oaire.citation.volume15
oaire.fundingReference.awardNumber1210736
oaire.fundingReference.funderNameAgencia Nacional de Investigación y Desarrollo (ANID)
udla.curacion.controljmvg
udla.oecd.area1 Ciencias Naturales
udla.oecd.discipline1.6.3 Virología
udla.oecd.subarea1.6 Ciencias Biológicas

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
372.pdf
Size:
3.74 MB
Format:
Adobe Portable Document Format

Collections